Navigation Links
Researcher finds potential new use for old drugs
Date:11/12/2013

PULLMAN, Wash. A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found.

Researchers discovered that simple modifications to the drug furamidine have a major impact on its ability to affect specific human proteins involved in the on-off switches of certain genes.

"This was rather unexpected, given how relatively simple the molecules are that we modified and how difficult it has been to affect these proteins," said Gregory Poon, pharmaceutical scientist at Washington State University.

The proteins known as transcription factors regulate the expression of genes in a highly coordinated and intricate manner, making them attractive targets for therapeutic drugs. But it has proven difficult to design drugs to affect them, Poon said.

"For this reason, they have been called undruggable," he said. "Recently, however, scientists have been making headway in targeting these transcription factors with drugs, and now our results suggest this class of drugs can be a useful addition to the arsenal."

Furamidine belongs to a family of drugs known as heterocyclic dications. The drug has a long history of use in serious parasitic diseases such as malaria, African sleeping sickness and PCP, a common infection in HIV/AIDS.

"There is tremendous knowledge and experience with using furamidine and related drugs in humans, so these drugs have an important advantage over other classes of drugs that are relatively behind in clinical experience," Poon said.

Poon collaborated with researchers at Georgia State University. The team found that derivatives of furamidine can target a specific transcription factor known as PU.1.

PU.1 is a major factor in development and function of the human immune system, and it plays important roles in diseases such as some leukemias, multiple sclerosis and diabetes. PU.1 is also a member of a large family of related transcription factors, known as ETS, that is involved in a broader range of cancers and other diseases.

"I am fortunate to be working with some of the best people in this area," Poon said, referring to his collaborators, Dave Boykin and David Wilson of Georgia State University. "The challenge now is to fine-tune this class of drugs to make them as specific as possible to other ETS-family transcription factors as well."


'/>"/>

Contact: Gregory Poon
gpoon@wsu.edu
509-335-8341
Washington State University
Source:Eurekalert

Related biology news :

1. Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find
2. Wayne State researchers discover specific inhibitor for rheumatoid arthritis treatment
3. Protein illustrates muscle damage: McMaster researchers
4. NSF awards to UT Arlington researchers will fuel sustainable solutions
5. Researchers uncover origins of cattle farming in China
6. UT Southwestern researchers identify how body clock affects inflammation
7. Researchers suggest plan to address hypoxia in Gulf of Mexico
8. Researchers advocate for climate adaptation science
9. UMMS researchers answer century old question about 3D structure of mitotic chromosomes
10. NIH funds researchers using light to control and monitor neural activity
11. Researchers regrow hair, cartilage, bone, soft tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... ISTANBUL , June 9, 2016  Perkotek an innovation leader in attendance control ... to seamlessly log work hours, for employers to make sure the right employees are ... Logo - http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016   ... the first pluripotent stem cell-derived islet replacement therapy for ... two presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, ... 22nd to 25th at Moscone West in San Francisco.  ... Details of the presentations are as follows:Event: , Focus ...
Breaking Biology Technology: